HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies

PURPOSE: Targeted therapies have resulted in major advances in the treatment of HER2-positive breast cancers. Despite this, up to 70% of patients will develop resistance to treatment within 2 years and new strategies for targeting resistant disease are needed. METHODS: To identify potential resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Tracey, Natasha, Creedon, Helen, Kemp, Alain J., Culley, Jayne, Muir, Morwenna, Klinowska, Teresa, Brunton, Valerie G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997276/
https://www.ncbi.nlm.nih.gov/pubmed/31705351
http://dx.doi.org/10.1007/s10549-019-05489-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997276/
https://www.ncbi.nlm.nih.gov/pubmed/31705351
http://dx.doi.org/10.1007/s10549-019-05489-1

Ejemplares similares